Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates

被引：0

作者：

Von Hoff, Daniel D.

Ervin, Thomas J.

Arena, Francis P.

Chiorean, E. Gabriela

Infante, Jeffrey R.

Moore, Malcolm J.

Seay, Thomas E.

Tjulandin, Sergei

Ma, Wen Wee

Saleh, Mansoor N.

Harris, Marion

Reni, Michele

Ramanathan, Ramesh K.

Tabernero, Josep

Hidalgo, Manuel

Van Cutsem, Eric

Goldstein, David

Wei, Xinyu

Iglesias, Jose Luis

Renschler, Markus Frederic

机构：

[1] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA

[2] Florida Canc Specialists, Englewood, FL USA

[3] Arena Oncol Associates, Lake Success, NY USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Tennessee Oncol, Nashville, TN USA

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[8] Atlanta Canc Care, Atlanta, GA USA

[9] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia

[10] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[11] Georgia Canc Specialists PC, Atlanta, GA USA

[12] Southern Hlth, East Bentleigh, Vic, Australia

[13] Univ Milan, Osped San Raffaele, Ist Ricovero & Cura Carattere Sci, I-20127 Milan, Italy

[14] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA

[15] Vall dHebron Univ Hosp, Barcelona, Spain

[16] Ctr Integral Oncol Clara Campal, Madrid, Spain

[17] Katholieke Univ Leuven Hosp, Louvain, Belgium

[18] Prince Wales Hosp, Sydney, NSW, Australia

[19] Celgene Corp, Summit, NJ USA

[20] Bionomics Ltd, Thebarton, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4005

引用

页数：1

共 50 条

[41] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
Ikeda, Masafumi
Ueno, Hideki
Ueno, Makoto
Mizuno, Nobumasa
Ioka, Tatsuya
Omuro, Yasushi
Nakajima, Takako
Furuse, Junji
ANNALS OF ONCOLOGY, 2014, 25
[42] Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial
Reni, Michele
Zanon, Silvia
Peretti, Umberto
Chiaravalli, Marta
Barone, Diletta
Pircher, Chiara
Balzano, Gianpaolo
Macchini, Marina
Romi, Silvia
Gritti, Elena
Mazza, Elena
Nicoletti, Roberto
Doglioni, Claudio
Falconi, Massimo
Gianni, Luca
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10): : 691 - 697
[43] Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns
Sahai, Vaibhav
Tabernero, Josep
Van Cutsem, Eric
Reni, Michele
Tempero, Margaret A.
O'Reilly, Eileen Mary
Berlin, Jordan
Riess, Hanno
Goldstein, David
Li, Mingyu
Lu, Brian
Ferrara, Stefano
Philip, Philip Agop
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[44] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
Vogel, A.
Penenberg, D.
McGovern, D.
Romano, A.
Michael, S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
[45] Gemcitabine plus nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGEO study
Zaibet, S.
Hautefeuille, V.
Auclin, E.
Lievre, A.
Tougeron, D.
Sarabi, M.
Gilabert, M.
Wasselin, J.
Edeline, J.
Artru, P.
Bechade, D.
Morin, C.
Taieb, J.
Pernot, S.
ANNALS OF ONCOLOGY, 2020, 31 : S213 - S214
[46] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
Jin, Min
Liu, Hong-Li
Xue, Jun
Ma, Hong
Liu, Jun-Li
Lin, Zhen-Yu
Wang, Jing
Bao, Le-Qun
Luo, Zhi-Guo
Yu, Xiong-Jie
Li, Shuang
Hu, Jian-Li
Zhang, Tao
ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
[47] Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
Bahary, Nathan
Wang-Gillam, Andrea
Haraldsdottir, Sigurdis
Somer, Bradley G.
Lee, Jin S.
O'Rourke, Mark Allen
Nayak-Kapoor, Asha
Beatty, Gregory Lawrence
Liu, Mingen
Delman, Devora
Rossi, Gabriela R.
Kennedy, Eugene Paul
Vahanian, Nicholas N.
Link, Charles J.
Garrido-Laguna, Ignacio
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[48] Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.
Assenat, Eric
De La Fouchardiere, Christelle
Mollevi, Caroline
Samalin, Emmanuelle
Portales, Fabienne
Desseigne, Francoise
Carenco, Christophe
Dupuy, Marie
Lopez-Martinez, Ernesto
Fiess, Catherine
Mazard, Thibault
Ychou, Marc
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[49] Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
Reni, Michele
Riess, Hanno
O'Reilly, Eileen Mary
Park, Joon Oh
Hatoum, Hassan
Saez, Berta Laquente
Salminen, Tapio
Oettle, Helmut
Lopez, Rafael
Dowden, Scot D.
Karthaus, Meinolf
Tabernero, Josep
Van Cutsem, Eric
Philip, Philip Agop
Goldstein, David
Berlin, Jordan
Tempero, Margaret A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
Ko, A.
Reni, M.
Riess, H.
Pelzer, U.
O'Reilly, E. M.
Winter, J.
Oh, D. Y.
Li, C. P.
Tortora, G.
Chang, H. M.
Lopez, C. D.
Tabernero, J.
Van Cutsem, E.
Philip, P.
Goldstein, D.
Berlin, J. D.
Ferrara, S.
Li, M.
Lu, B.
Romano, A.
Marks, H.
Biankin, A.
Tempero, M. A.
PANCREAS, 2019, 48 (10) : 1464 - 1464

← 1 2 3 4 5 →